A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Test Efficacy and Safety of Magnetic Resonance Imaging-Based Thrombolysis in Wake-up Stroke (WAKE-UP) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of Stroke Année : 2014

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Test Efficacy and Safety of Magnetic Resonance Imaging-Based Thrombolysis in Wake-up Stroke (WAKE-UP)

Götz Thomalla
  • Fonction : Auteur
Jochen Fiebach
  • Fonction : Auteur
Leif Østergaard
  • Fonction : Auteur
Salvador Pedraza
  • Fonction : Auteur
Vincent Thijs
  • Fonction : Auteur
Norbert Nighoghossian
Keith Muir
  • Fonction : Auteur
Martin Ebinger
  • Fonction : Auteur
Bastian Cheng
  • Fonction : Auteur
Ivana Galinovic
  • Fonction : Auteur
Tae-Hee Cho
  • Fonction : Auteur
  • PersonId : 918240
Josep Puig
  • Fonction : Auteur
Florent Boutitie
  • Fonction : Auteur
Claus Simonsen
  • Fonction : Auteur
Matthias Endres
  • Fonction : Auteur
Jens Fiehler
  • Fonction : Auteur
Christian Gerloff
  • Fonction : Auteur

Résumé

Rationale In about 20% of acute ischemic stroke patients stroke occurs during sleep. These patients are generally excluded from intravenous thrombolysis. MRI can identify patients within the time-window for thrombolysis (≤4·5 h from symptom onset) by a mismatch between the acute ischemic lesion visible on diffusion weighted imaging (DWI) but not visible on fluid-attenuated inversion recovery (FLAIR) imaging. Aims and hypothesis The study aims to test the efficacy and safety of MRI-guided thrombolysis with tissue plasminogen activator (rtPA) in ischemic stroke patients with unknown time of symptom onset, e.g., waking up with stroke symptoms. We hypothesize that stroke patients with unknown time of symptom onset with a DWI-FLAIR-mismatch pattern on MRI will have improved outcome when treated with rtPA compared to placebo. Design WAKE-UP is an investigator initiated, European, multicentre, randomized, double-blind, placebo-controlled clinical trial. Patients with unknown time of symptom onset who fulfil clinical inclusion criteria (disabling neurological deficit, no contraindications against thrombolysis) will be studied by MRI. Patients with MRI findings of a DWI-FLAIR-mismatch will be randomised to either treatment with rtPA or placebo. Study outcome The primary efficacy endpoint will be favourable outcome defined by modified Rankin Scale 0–1 at day 90. The primary safety outcome measures will be mortality and death or dependency defined by modified Rankin Scale 4–6 at 90 days. Discussion If positive, WAKE-UP is expected to change clinical practice making effective and safe treatment available for a large group of acute stroke patients currently excluded from specific acute therapy.
Fichier non déposé

Dates et versions

hal-04167078 , version 1 (20-07-2023)

Identifiants

Citer

Götz Thomalla, Jochen Fiebach, Leif Østergaard, Salvador Pedraza, Vincent Thijs, et al.. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Test Efficacy and Safety of Magnetic Resonance Imaging-Based Thrombolysis in Wake-up Stroke (WAKE-UP). International Journal of Stroke, 2014, 9 (6), pp.829-836. ⟨10.1111/ijs.12011⟩. ⟨hal-04167078⟩

Collections

HCL
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More